NOVARTIS: Reimagining Medicine Through Digital Transformation and R&D

Words: Susanne Kohout, Country President and Managing Director, Novartis Hellas

The Covid-19 pandemic has triggered the pharmaceutical sector to accelerate its digital transformation to not only reshape our sector but to also create better experiences for patients and physicians. In the post-Covid-19 era, telemedicine, virtual trials, remote patient monitoring, and AI are expected to redefine the future of healthcare. Global health is data-dependent and Big Data is a great tool to understand, improve and evolve healthcare. Greece is very well positioned in this area, due to its e-prescription system and as one of the few EU countries with a thorough Covid-19 registry. The Ministry of Digital Infrastructure has been a catalyst, and now is the time to establish a concrete framework, as per the WHO OneΗealth governance. Cooperation among all stakeholders is key. 

Novartis’s vision is to reimagine medicine to improve and extend people’s lives, powered by data science and digital technologies. AAV-based therapies, cell and gene therapies and CRISPR-based technologies serve our goal to produce breakthroughs and address major unmet needs. We are currently pursuing 12 major projects to build large-scale digital solutions, including massive clinical databases, improving our people’s digital capabilities, and forging partnerships with leading technology companies such as Microsoft, Amazon, Google, and HP.

Article Source: p. 39, The Magazine of the American-Hellenic Chamber of Commerce ‘Business Partners’